KALYONCU, U. Et Al. 2022. Effectiveness and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data. Clinical and Experimental Rheumatology , vol.40, no.11 , 2071-2077.

KALYONCU, U., BİLGİN, E., Erden, A., SATIŞ, H., TUFAN, A., Tekgöz, E., ... ATEŞ, A.(2022). Effectiveness and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data. Clinical and Experimental Rheumatology , vol.40, no.11, 2071-2077.

KALYONCU, UMUT Et Al. "Effectiveness and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data," Clinical and Experimental Rheumatology , vol.40, no.11, 2071-2077, 2022

KALYONCU, UMUT Et Al. "Effectiveness and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data." Clinical and Experimental Rheumatology , vol.40, no.11, pp.2071-2077, 2022

KALYONCU, U. Et Al. (2022) . "Effectiveness and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data." Clinical and Experimental Rheumatology , vol.40, no.11, pp.2071-2077.

@article{article, author={UMUT KALYONCU Et Al. }, title={Effectiveness and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data}, journal={Clinical and Experimental Rheumatology}, year=2022, pages={2071-2077} }